Progyny, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Progyny, Inc. (PGNY) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$52.59 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-05-06
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$52.59M.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$40.48M, a 459.80% decline year-over-year.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $11.25M, a 4647.68% increase year-over-year.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was $237.00K.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $21.11M.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$10.08M, a 112.56% decline from fiscal 2019.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $80.25M.
- Progyny, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was -$4.56M, a 371.67% decline from fiscal 2017.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$52.59M 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $21.11M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $21.92M 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | -$21.56M 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | -$40.48M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | -$10.08M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | -$26.42M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | -$30.99M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $11.25M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $80.25M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $7.54M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $171.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $237.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$4.56M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$4.52M 10-Q · filed 2019-12-06 | |||
| 2017-12-31 | $1.68M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |